Medtronic, Zimmer Biomet best positioned for recovery, according to analysts

Alan Condon -   Print  |

The medtech sector looks more certain to recover in 2021, with Morgan Stanley analysts betting on Medtronic and Zimmer Biomet stocks to perform well next year, according to Seeking Alpha.

Three notes:

1. The analysts predict 2021 performance to be driven by multiple expansion on rising earnings, and label Zimmer Biomet and Medtronic as the "best large caps to play implantable recovery," according to the report.

2. Wells Fargo analysts project industry growth to accelerate by the second half of 2021.

3. Accelerated growth is expected to be driven by the surgical backlog caused by the COVID-19 pandemic earlier this year.

More articles on devices:
How CMS' changes will affect spine surgeons in 2021 — Prior authorization, fee cuts & more
Former orthopedic practice owner gets 5 years in prison for illegally prescribing opioids
Surgeons' brand exceeds patient outcomes — How you should build your practice's brand

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers